LockdownV1, Main, Exploration, bibRecord, 000841

[Estimated Effect of COVID-19 Lockdown on Skin Tumor Size and Survival: An Exponential Growth Model].

Identifieur interne : 000841 ( Main/Exploration ); précédent : 000840; suivant : 000842

[Estimated Effect of COVID-19 Lockdown on Skin Tumor Size and Survival: An Exponential Growth Model].

Auteurs : A. Tejera-Vaquerizo [Espagne] ; J. Ca Ueto [Espagne] ; A. Toll [Espagne] ; J. Santos-Juanes [Espagne] ; A. Jaka [Espagne] ; C. Ferrandiz-Pulido [Espagne] ; O. Sanmartín [Espagne] ; S. Ribero [Italie] ; D. Moreno-Ramírez [Espagne] ; F. Almazán [Espagne] ; M J Fuente [Espagne] ; S. Podlipnik [Espagne] ; E. Nagore [Espagne]

Source :

Actas dermo-sifiliograficas [ 1578-2190 ] ; 2020.

RBID : pubmed:32513393

Descripteurs français

KwdFr :
- Accessibilité des services de santé (MeSH), Algorithmes (MeSH), Betacoronavirus (MeSH), Carcinome épidermoïde (anatomopathologie), Carcinome épidermoïde (mortalité), Charge tumorale (MeSH), Délai jusqu'au traitement (MeSH), Espagne (épidémiologie), Facteurs sexuels (MeSH), Facteurs temps (MeSH), Facteurs âges (MeSH), Femelle (MeSH), Humains (MeSH), Infections à coronavirus (épidémiologie), Mâle (MeSH), Mélanome (anatomopathologie), Mélanome (mortalité), Pandémies (MeSH), Pneumopathie virale (épidémiologie), Quarantaine (MeSH), Retard de diagnostic (effets indésirables), Retard de diagnostic (statistiques et données numériques), Surveillance de la santé publique (méthodes), Tumeurs cutanées (anatomopathologie), Tumeurs cutanées (mortalité), Tumeurs de la tête et du cou (anatomopathologie), Tumeurs de la tête et du cou (mortalité), Études rétrospectives (MeSH).
MESH :
- anatomopathologie : Carcinome épidermoïde, Mélanome, Tumeurs cutanées, Tumeurs de la tête et du cou.
- effets indésirables : Retard de diagnostic.
- mortalité : Carcinome épidermoïde, Mélanome, Tumeurs cutanées, Tumeurs de la tête et du cou.
- méthodes : Surveillance de la santé publique.
- statistiques et données numériques : Retard de diagnostic.
- épidémiologie : Espagne, Infections à coronavirus, Pneumopathie virale.
- Accessibilité des services de santé, Algorithmes, Betacoronavirus, Charge tumorale, Délai jusqu'au traitement, Facteurs sexuels, Facteurs temps, Facteurs âges, Femelle, Humains, Mâle, Pandémies, Quarantaine, Études rétrospectives.
Wicri :
- geographic : Espagne.

English descriptors

KwdEn :
- Age Factors (MeSH), Algorithms (MeSH), Betacoronavirus (MeSH), COVID-19 (MeSH), Carcinoma, Squamous Cell (mortality), Carcinoma, Squamous Cell (pathology), Coronavirus Infections (epidemiology), Delayed Diagnosis (adverse effects), Delayed Diagnosis (statistics & numerical data), Female (MeSH), Head and Neck Neoplasms (mortality), Head and Neck Neoplasms (pathology), Health Services Accessibility (MeSH), Humans (MeSH), Male (MeSH), Melanoma (mortality), Melanoma (pathology), Pandemics (MeSH), Pneumonia, Viral (epidemiology), Public Health Surveillance (methods), Quarantine (MeSH), Retrospective Studies (MeSH), SARS-CoV-2 (MeSH), Sex Factors (MeSH), Skin Neoplasms (mortality), Skin Neoplasms (pathology), Spain (epidemiology), Time Factors (MeSH), Time-to-Treatment (MeSH), Tumor Burden (MeSH).
MESH :
- geographic , epidemiology : Spain.
- adverse effects : Delayed Diagnosis.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- methods : Public Health Surveillance.
- mortality : Carcinoma, Squamous Cell, Head and Neck Neoplasms, Melanoma, Skin Neoplasms.
- pathology : Carcinoma, Squamous Cell, Head and Neck Neoplasms, Melanoma, Skin Neoplasms.
- statistics & numerical data : Delayed Diagnosis.
- Age Factors, Algorithms, Betacoronavirus, COVID-19, Female, Health Services Accessibility, Humans, Male, Pandemics, Quarantine, Retrospective Studies, SARS-CoV-2, Sex Factors, Time Factors, Time-to-Treatment, Tumor Burden.

Abstract

Background and objectives

Spain is in a situation of indefinite lockdown due to the ongoing coronavirus disease 2019 (COVID-19) pandemic. One of the consequences of this lockdown is delays in medical and surgical procedures for common diseases. The aim of this study was to model the impact on survival of tumor growth caused by such delays in patients with squamous cell carcinoma (SCC) and melanoma.

Material and methods

Multicenter, retrospective, observational cohort study. We constructed an exponential growth model for both SCC and melanoma to estimate tumor growth between patient-reported onset and surgical excision at different time points.

Results

Data from 200 patients with SCC of the head and neck and 1000 patients with cutaneous melanoma were included. An exponential growth curve was calculated for each tumor type and we estimated tumor size after 1, 2, and 3 months of potential surgical delay. The proportion of patients with T3 SCC (diameter >4cm or thickness >6 mm) increased from 41.5% (83 patients) in the initial study group to an estimated 58.5%, 70.5%, and 72% after 1, 2, and 3 months of delay. Disease-specific survival at 2, 5, and 10 years in patients whose surgery was delayed by 3 months decreased by 6.2%, 8.2%, and 5.2%, respectively. The proportion of patients with ultrathick melanoma (>6 mm) increased from 6.9% in the initial study group to 21.9%, 30.2%, and 30.2% at 1, 2, and 3 months. Five- and 10-year disease-specific survival both decreased by 14.4% in patients treated after a potential delay of 3 months.

Conclusions

In the absence of adequate diagnosis and treatment of SCC and melanoma in the current lockdown situation in Spain, we can expect to see to a considerable increase in large and thick SCCs and melanomas. Efforts must be taken to encourage self-examination and facilitate access to dermatologists in order to prevent further delays.

DOI: 10.1016/j.ad.2020.05.001
PubMed: 32513393
PubMed Central: PMC7502279

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 002455
to stream Main, to step Curation: 002455

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Estimated Effect of COVID-19 Lockdown on Skin Tumor Size and Survival: An Exponential Growth Model].</title>
<author><name sortKey="Tejera Vaquerizo, A" sort="Tejera Vaquerizo, A" uniqKey="Tejera Vaquerizo A" first="A" last="Tejera-Vaquerizo">A. Tejera-Vaquerizo</name>
<affiliation wicri:level="1"><nlm:affiliation>Servicio de Dermatología, Instituto Dermatológico GlobalDerm, Palma del Río, Córdoba, España. Electronic address: antoniotejera@aedv.es.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Dermatología, Instituto Dermatológico GlobalDerm, Palma del Río, Córdoba</wicri:regionArea>
<wicri:noRegion>Córdoba</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ca Ueto, J" sort="Ca Ueto, J" uniqKey="Ca Ueto J" first="J" last="Ca Ueto">J. Ca Ueto</name>
<affiliation wicri:level="1"><nlm:affiliation>Servicio de Dermatología, Hospital Universitario de Salamanca, Salamanca, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Dermatología, Hospital Universitario de Salamanca, Salamanca</wicri:regionArea>
<wicri:noRegion>Salamanca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Toll, A" sort="Toll, A" uniqKey="Toll A" first="A" last="Toll">A. Toll</name>
<affiliation wicri:level="3"><nlm:affiliation>Servicio de Dermatología, Hospital Clìnic de Barcelona, Barcelona, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Dermatología, Hospital Clìnic de Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Santos Juanes, J" sort="Santos Juanes, J" uniqKey="Santos Juanes J" first="J" last="Santos-Juanes">J. Santos-Juanes</name>
<affiliation wicri:level="1"><nlm:affiliation>Servicio de Dermatología, Hospital Universitario Central de Asturias, Oviedo, Asturias, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Dermatología, Hospital Universitario Central de Asturias, Oviedo, Asturias</wicri:regionArea>
<wicri:noRegion>Asturias</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jaka, A" sort="Jaka, A" uniqKey="Jaka A" first="A" last="Jaka">A. Jaka</name>
<affiliation wicri:level="3"><nlm:affiliation>Servicio de Dermatología, Hospital Germans Trial i Pujol, Badalona, Barcelona, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Dermatología, Hospital Germans Trial i Pujol, Badalona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ferrandiz Pulido, C" sort="Ferrandiz Pulido, C" uniqKey="Ferrandiz Pulido C" first="C" last="Ferrandiz-Pulido">C. Ferrandiz-Pulido</name>
<affiliation wicri:level="3"><nlm:affiliation>Servicio de Dermatología, Hospital Universitario Vall d'Hebron, Barcelona, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Dermatología, Hospital Universitario Vall d'Hebron, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sanmartin, O" sort="Sanmartin, O" uniqKey="Sanmartin O" first="O" last="Sanmartín">O. Sanmartín</name>
<affiliation wicri:level="1"><nlm:affiliation>Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia</wicri:regionArea>
<wicri:noRegion>Valencia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ribero, S" sort="Ribero, S" uniqKey="Ribero S" first="S" last="Ribero">S. Ribero</name>
<affiliation wicri:level="1"><nlm:affiliation>Departamento de Dermatología, Hospital Universitario de Turín, Turín, Italia.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Departamento de Dermatología, Hospital Universitario de Turín, Turín</wicri:regionArea>
<wicri:noRegion>Turín</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moreno Ramirez, D" sort="Moreno Ramirez, D" uniqKey="Moreno Ramirez D" first="D" last="Moreno-Ramírez">D. Moreno-Ramírez</name>
<affiliation wicri:level="1"><nlm:affiliation>Unidad de Melanoma, Servicio de Dermatología Médico-Quirúrgica, Hospital Universitario Virgen Macarena, Sevilla, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Unidad de Melanoma, Servicio de Dermatología Médico-Quirúrgica, Hospital Universitario Virgen Macarena, Sevilla</wicri:regionArea>
<wicri:noRegion>Sevilla</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Almazan, F" sort="Almazan, F" uniqKey="Almazan F" first="F" last="Almazán">F. Almazán</name>
<affiliation wicri:level="1"><nlm:affiliation>Unidad de Gestión Clínica de Dermatología, Hospital Universitario San Cecilio, Granada, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Unidad de Gestión Clínica de Dermatología, Hospital Universitario San Cecilio, Granada</wicri:regionArea>
<wicri:noRegion>Granada</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fuente, M J" sort="Fuente, M J" uniqKey="Fuente M" first="M J" last="Fuente">M J Fuente</name>
<affiliation wicri:level="3"><nlm:affiliation>Servicio de Dermatología, Hospital Germans Trial i Pujol, Badalona, Barcelona, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Dermatología, Hospital Germans Trial i Pujol, Badalona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Podlipnik, S" sort="Podlipnik, S" uniqKey="Podlipnik S" first="S" last="Podlipnik">S. Podlipnik</name>
<affiliation wicri:level="3"><nlm:affiliation>Servicio de Dermatología, Hospital Clìnic de Barcelona, Barcelona, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Dermatología, Hospital Clìnic de Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nagore, E" sort="Nagore, E" uniqKey="Nagore E" first="E" last="Nagore">E. Nagore</name>
<affiliation wicri:level="1"><nlm:affiliation>Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia</wicri:regionArea>
<wicri:noRegion>Valencia</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32513393</idno>
<idno type="pmid">32513393</idno>
<idno type="doi">10.1016/j.ad.2020.05.001</idno>
<idno type="pmc">PMC7502279</idno>
<idno type="wicri:Area/Main/Corpus">002455</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">002455</idno>
<idno type="wicri:Area/Main/Curation">002455</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">002455</idno>
<idno type="wicri:Area/Main/Exploration">002455</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Estimated Effect of COVID-19 Lockdown on Skin Tumor Size and Survival: An Exponential Growth Model].</title>
<author><name sortKey="Tejera Vaquerizo, A" sort="Tejera Vaquerizo, A" uniqKey="Tejera Vaquerizo A" first="A" last="Tejera-Vaquerizo">A. Tejera-Vaquerizo</name>
<affiliation wicri:level="1"><nlm:affiliation>Servicio de Dermatología, Instituto Dermatológico GlobalDerm, Palma del Río, Córdoba, España. Electronic address: antoniotejera@aedv.es.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Dermatología, Instituto Dermatológico GlobalDerm, Palma del Río, Córdoba</wicri:regionArea>
<wicri:noRegion>Córdoba</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ca Ueto, J" sort="Ca Ueto, J" uniqKey="Ca Ueto J" first="J" last="Ca Ueto">J. Ca Ueto</name>
<affiliation wicri:level="1"><nlm:affiliation>Servicio de Dermatología, Hospital Universitario de Salamanca, Salamanca, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Dermatología, Hospital Universitario de Salamanca, Salamanca</wicri:regionArea>
<wicri:noRegion>Salamanca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Toll, A" sort="Toll, A" uniqKey="Toll A" first="A" last="Toll">A. Toll</name>
<affiliation wicri:level="3"><nlm:affiliation>Servicio de Dermatología, Hospital Clìnic de Barcelona, Barcelona, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Dermatología, Hospital Clìnic de Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Santos Juanes, J" sort="Santos Juanes, J" uniqKey="Santos Juanes J" first="J" last="Santos-Juanes">J. Santos-Juanes</name>
<affiliation wicri:level="1"><nlm:affiliation>Servicio de Dermatología, Hospital Universitario Central de Asturias, Oviedo, Asturias, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Dermatología, Hospital Universitario Central de Asturias, Oviedo, Asturias</wicri:regionArea>
<wicri:noRegion>Asturias</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jaka, A" sort="Jaka, A" uniqKey="Jaka A" first="A" last="Jaka">A. Jaka</name>
<affiliation wicri:level="3"><nlm:affiliation>Servicio de Dermatología, Hospital Germans Trial i Pujol, Badalona, Barcelona, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Dermatología, Hospital Germans Trial i Pujol, Badalona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ferrandiz Pulido, C" sort="Ferrandiz Pulido, C" uniqKey="Ferrandiz Pulido C" first="C" last="Ferrandiz-Pulido">C. Ferrandiz-Pulido</name>
<affiliation wicri:level="3"><nlm:affiliation>Servicio de Dermatología, Hospital Universitario Vall d'Hebron, Barcelona, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Dermatología, Hospital Universitario Vall d'Hebron, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sanmartin, O" sort="Sanmartin, O" uniqKey="Sanmartin O" first="O" last="Sanmartín">O. Sanmartín</name>
<affiliation wicri:level="1"><nlm:affiliation>Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia</wicri:regionArea>
<wicri:noRegion>Valencia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ribero, S" sort="Ribero, S" uniqKey="Ribero S" first="S" last="Ribero">S. Ribero</name>
<affiliation wicri:level="1"><nlm:affiliation>Departamento de Dermatología, Hospital Universitario de Turín, Turín, Italia.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Departamento de Dermatología, Hospital Universitario de Turín, Turín</wicri:regionArea>
<wicri:noRegion>Turín</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moreno Ramirez, D" sort="Moreno Ramirez, D" uniqKey="Moreno Ramirez D" first="D" last="Moreno-Ramírez">D. Moreno-Ramírez</name>
<affiliation wicri:level="1"><nlm:affiliation>Unidad de Melanoma, Servicio de Dermatología Médico-Quirúrgica, Hospital Universitario Virgen Macarena, Sevilla, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Unidad de Melanoma, Servicio de Dermatología Médico-Quirúrgica, Hospital Universitario Virgen Macarena, Sevilla</wicri:regionArea>
<wicri:noRegion>Sevilla</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Almazan, F" sort="Almazan, F" uniqKey="Almazan F" first="F" last="Almazán">F. Almazán</name>
<affiliation wicri:level="1"><nlm:affiliation>Unidad de Gestión Clínica de Dermatología, Hospital Universitario San Cecilio, Granada, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Unidad de Gestión Clínica de Dermatología, Hospital Universitario San Cecilio, Granada</wicri:regionArea>
<wicri:noRegion>Granada</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fuente, M J" sort="Fuente, M J" uniqKey="Fuente M" first="M J" last="Fuente">M J Fuente</name>
<affiliation wicri:level="3"><nlm:affiliation>Servicio de Dermatología, Hospital Germans Trial i Pujol, Badalona, Barcelona, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Dermatología, Hospital Germans Trial i Pujol, Badalona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Podlipnik, S" sort="Podlipnik, S" uniqKey="Podlipnik S" first="S" last="Podlipnik">S. Podlipnik</name>
<affiliation wicri:level="3"><nlm:affiliation>Servicio de Dermatología, Hospital Clìnic de Barcelona, Barcelona, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Dermatología, Hospital Clìnic de Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nagore, E" sort="Nagore, E" uniqKey="Nagore E" first="E" last="Nagore">E. Nagore</name>
<affiliation wicri:level="1"><nlm:affiliation>Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia, España.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia</wicri:regionArea>
<wicri:noRegion>Valencia</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Actas dermo-sifiliograficas</title>
<idno type="eISSN">1578-2190</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors (MeSH)</term>
<term>Algorithms (MeSH)</term>
<term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Carcinoma, Squamous Cell (mortality)</term>
<term>Carcinoma, Squamous Cell (pathology)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Delayed Diagnosis (adverse effects)</term>
<term>Delayed Diagnosis (statistics & numerical data)</term>
<term>Female (MeSH)</term>
<term>Head and Neck Neoplasms (mortality)</term>
<term>Head and Neck Neoplasms (pathology)</term>
<term>Health Services Accessibility (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Male (MeSH)</term>
<term>Melanoma (mortality)</term>
<term>Melanoma (pathology)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Public Health Surveillance (methods)</term>
<term>Quarantine (MeSH)</term>
<term>Retrospective Studies (MeSH)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Sex Factors (MeSH)</term>
<term>Skin Neoplasms (mortality)</term>
<term>Skin Neoplasms (pathology)</term>
<term>Spain (epidemiology)</term>
<term>Time Factors (MeSH)</term>
<term>Time-to-Treatment (MeSH)</term>
<term>Tumor Burden (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Accessibilité des services de santé (MeSH)</term>
<term>Algorithmes (MeSH)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Carcinome épidermoïde (anatomopathologie)</term>
<term>Carcinome épidermoïde (mortalité)</term>
<term>Charge tumorale (MeSH)</term>
<term>Délai jusqu'au traitement (MeSH)</term>
<term>Espagne (épidémiologie)</term>
<term>Facteurs sexuels (MeSH)</term>
<term>Facteurs temps (MeSH)</term>
<term>Facteurs âges (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Mâle (MeSH)</term>
<term>Mélanome (anatomopathologie)</term>
<term>Mélanome (mortalité)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Quarantaine (MeSH)</term>
<term>Retard de diagnostic (effets indésirables)</term>
<term>Retard de diagnostic (statistiques et données numériques)</term>
<term>Surveillance de la santé publique (méthodes)</term>
<term>Tumeurs cutanées (anatomopathologie)</term>
<term>Tumeurs cutanées (mortalité)</term>
<term>Tumeurs de la tête et du cou (anatomopathologie)</term>
<term>Tumeurs de la tête et du cou (mortalité)</term>
<term>Études rétrospectives (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Delayed Diagnosis</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome épidermoïde</term>
<term>Mélanome</term>
<term>Tumeurs cutanées</term>
<term>Tumeurs de la tête et du cou</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Retard de diagnostic</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Public Health Surveillance</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Carcinoma, Squamous Cell</term>
<term>Head and Neck Neoplasms</term>
<term>Melanoma</term>
<term>Skin Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Carcinome épidermoïde</term>
<term>Mélanome</term>
<term>Tumeurs cutanées</term>
<term>Tumeurs de la tête et du cou</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Surveillance de la santé publique</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Squamous Cell</term>
<term>Head and Neck Neoplasms</term>
<term>Melanoma</term>
<term>Skin Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Delayed Diagnosis</term>
</keywords>
<keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Retard de diagnostic</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Espagne</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Age Factors</term>
<term>Algorithms</term>
<term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Female</term>
<term>Health Services Accessibility</term>
<term>Humans</term>
<term>Male</term>
<term>Pandemics</term>
<term>Quarantine</term>
<term>Retrospective Studies</term>
<term>SARS-CoV-2</term>
<term>Sex Factors</term>
<term>Time Factors</term>
<term>Time-to-Treatment</term>
<term>Tumor Burden</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Accessibilité des services de santé</term>
<term>Algorithmes</term>
<term>Betacoronavirus</term>
<term>Charge tumorale</term>
<term>Délai jusqu'au traitement</term>
<term>Facteurs sexuels</term>
<term>Facteurs temps</term>
<term>Facteurs âges</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Pandémies</term>
<term>Quarantaine</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>Background and objectives</b>
</p>
<p>Spain is in a situation of indefinite lockdown due to the ongoing coronavirus disease 2019 (COVID-19) pandemic. One of the consequences of this lockdown is delays in medical and surgical procedures for common diseases. The aim of this study was to model the impact on survival of tumor growth caused by such delays in patients with squamous cell carcinoma (SCC) and melanoma.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>Material and methods</b>
</p>
<p>Multicenter, retrospective, observational cohort study. We constructed an exponential growth model for both SCC and melanoma to estimate tumor growth between patient-reported onset and surgical excision at different time points.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>Results</b>
</p>
<p>Data from 200 patients with SCC of the head and neck and 1000 patients with cutaneous melanoma were included. An exponential growth curve was calculated for each tumor type and we estimated tumor size after 1, 2, and 3 months of potential surgical delay. The proportion of patients with T3 SCC (diameter >4cm or thickness >6 mm) increased from 41.5% (83 patients) in the initial study group to an estimated 58.5%, 70.5%, and 72% after 1, 2, and 3 months of delay. Disease-specific survival at 2, 5, and 10 years in patients whose surgery was delayed by 3 months decreased by 6.2%, 8.2%, and 5.2%, respectively. The proportion of patients with ultrathick melanoma (>6 mm) increased from 6.9% in the initial study group to 21.9%, 30.2%, and 30.2% at 1, 2, and 3 months. Five- and 10-year disease-specific survival both decreased by 14.4% in patients treated after a potential delay of 3 months.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>Conclusions</b>
</p>
<p>In the absence of adequate diagnosis and treatment of SCC and melanoma in the current lockdown situation in Spain, we can expect to see to a considerable increase in large and thick SCCs and melanomas. Efforts must be taken to encourage self-examination and facilitate access to dermatologists in order to prevent further delays.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32513393</PMID>
<DateCompleted><Year>2020</Year>
<Month>10</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-2190</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>111</Volume>
<Issue>8</Issue>
<PubDate><Year>2020</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Actas dermo-sifiliograficas</Title>
<ISOAbbreviation>Actas Dermosifiliogr</ISOAbbreviation>
</Journal>
<ArticleTitle>[Estimated Effect of COVID-19 Lockdown on Skin Tumor Size and Survival: An Exponential Growth Model].</ArticleTitle>
<Pagination><MedlinePgn>629-638</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0001-7310(20)30142-3</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ad.2020.05.001</ELocationID>
<Abstract><AbstractText Label="Background and objectives" NlmCategory="UNASSIGNED">Spain is in a situation of indefinite lockdown due to the ongoing coronavirus disease 2019 (COVID-19) pandemic. One of the consequences of this lockdown is delays in medical and surgical procedures for common diseases. The aim of this study was to model the impact on survival of tumor growth caused by such delays in patients with squamous cell carcinoma (SCC) and melanoma.</AbstractText>
<AbstractText Label="Material and methods" NlmCategory="UNASSIGNED">Multicenter, retrospective, observational cohort study. We constructed an exponential growth model for both SCC and melanoma to estimate tumor growth between patient-reported onset and surgical excision at different time points.</AbstractText>
<AbstractText Label="Results" NlmCategory="UNASSIGNED">Data from 200 patients with SCC of the head and neck and 1000 patients with cutaneous melanoma were included. An exponential growth curve was calculated for each tumor type and we estimated tumor size after 1, 2, and 3 months of potential surgical delay. The proportion of patients with T3 SCC (diameter >4cm or thickness >6 mm) increased from 41.5% (83 patients) in the initial study group to an estimated 58.5%, 70.5%, and 72% after 1, 2, and 3 months of delay. Disease-specific survival at 2, 5, and 10 years in patients whose surgery was delayed by 3 months decreased by 6.2%, 8.2%, and 5.2%, respectively. The proportion of patients with ultrathick melanoma (>6 mm) increased from 6.9% in the initial study group to 21.9%, 30.2%, and 30.2% at 1, 2, and 3 months. Five- and 10-year disease-specific survival both decreased by 14.4% in patients treated after a potential delay of 3 months.</AbstractText>
<AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">In the absence of adequate diagnosis and treatment of SCC and melanoma in the current lockdown situation in Spain, we can expect to see to a considerable increase in large and thick SCCs and melanomas. Efforts must be taken to encourage self-examination and facilitate access to dermatologists in order to prevent further delays.</AbstractText>
<CopyrightInformation>© 2020 Published by Elsevier España, S.L.U. on behalf of AEDV.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tejera-Vaquerizo</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Servicio de Dermatología, Instituto Dermatológico GlobalDerm, Palma del Río, Córdoba, España. Electronic address: antoniotejera@aedv.es.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cañueto</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Servicio de Dermatología, Hospital Universitario de Salamanca, Salamanca, España.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Toll</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Servicio de Dermatología, Hospital Clìnic de Barcelona, Barcelona, España.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Santos-Juanes</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Servicio de Dermatología, Hospital Universitario Central de Asturias, Oviedo, Asturias, España.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jaka</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Servicio de Dermatología, Hospital Germans Trial i Pujol, Badalona, Barcelona, España.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ferrandiz-Pulido</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Servicio de Dermatología, Hospital Universitario Vall d'Hebron, Barcelona, España.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sanmartín</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia, España.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ribero</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Departamento de Dermatología, Hospital Universitario de Turín, Turín, Italia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Moreno-Ramírez</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Unidad de Melanoma, Servicio de Dermatología Médico-Quirúrgica, Hospital Universitario Virgen Macarena, Sevilla, España.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Almazán</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Unidad de Gestión Clínica de Dermatología, Hospital Universitario San Cecilio, Granada, España.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fuente</LastName>
<ForeName>M J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo><Affiliation>Servicio de Dermatología, Hospital Germans Trial i Pujol, Badalona, Barcelona, España.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Podlipnik</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Servicio de Dermatología, Hospital Clìnic de Barcelona, Barcelona, España.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nagore</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia, España.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>spa</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D064888">Observational Study</PublicationType>
</PublicationTypeList>
<VernacularTitle>Estimación del efecto en el tamaño y la supervivencia de los tumores cutáneos debido al confinamiento por COVID-19: modelo basado en un crecimiento exponencial.</VernacularTitle>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>05</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Spain</Country>
<MedlineTA>Actas Dermosifiliogr</MedlineTA>
<NlmUniqueID>0373062</NlmUniqueID>
<ISSNLinking>0001-7310</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057210" MajorTopicYN="N">Delayed Diagnosis</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006258" MajorTopicYN="N">Head and Neck Neoplasms</DescriptorName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006297" MajorTopicYN="N">Health Services Accessibility</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D062486" MajorTopicYN="N">Public Health Surveillance</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011790" MajorTopicYN="N">Quarantine</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061665" MajorTopicYN="N">Time-to-Treatment</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D047368" MajorTopicYN="Y">Tumor Burden</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 virus disease</Keyword>
<Keyword MajorTopicYN="N">Cutaneous squamous cell carcinoma</Keyword>
<Keyword MajorTopicYN="N">Early diagnosis</Keyword>
<Keyword MajorTopicYN="N">Lockdown</Keyword>
<Keyword MajorTopicYN="N">Melanoma</Keyword>
<Keyword MajorTopicYN="N">Prognosis</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>05</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>6</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>10</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>6</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32513393</ArticleId>
<ArticleId IdType="pii">S0001-7310(20)30142-3</ArticleId>
<ArticleId IdType="doi">10.1016/j.ad.2020.05.001</ArticleId>
<ArticleId IdType="pmc">PMC7502279</ArticleId>
</ArticleIdList>
<pmc-dir>pmcsd</pmc-dir>
        <ReferenceList><Reference><Citation>Eur Heart J. 2020 May 14;41(19):1852-1853</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32297932</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Exp Dermatol. 2018 Dec;43(8):876-882</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29756221</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Actas Dermosifiliogr. 2013 Jun;104(5):367-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23683506</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Urol. 2020 Jul;78(1):e14-e15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32349936</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Dermatol. 2018 Feb 1;154(2):175-181</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29261835</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Surg. 1964 Feb;159:161-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14119181</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Surg Oncol. 2020 Jun;27(6):1717-1720</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32270420</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Eur Acad Dermatol Venereol. 2020 Apr 7;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32259328</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Invest Dermatol. 2012 Apr;132(4):1215-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22217744</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oral Dis. 2020 Apr 19;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32306459</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Actas Dermosifiliogr. 2016 May;107(4):318-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26852370</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Feb 25;323(8):709-710</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31999307</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Acad Dermatol. 2010 Sep;63(3):404-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20598396</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Acad Dermatol. 2014 Mar;70(3):456-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24373780</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Actas Dermosifiliogr. 2013 Nov;104(9):789-99</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23622931</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Cancer. 1966 Mar;20(1):74-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5327764</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Actas Dermosifiliogr. 2011 Oct;102(8):605-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21742301</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Melanoma Res. 2011 Apr;21(2):131-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21183860</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Espagne</li>
<li>Italie</li>
</country>
<region><li>Catalogne</li>
</region>
<settlement><li>Barcelone</li>
</settlement>
</list>
<tree><country name="Espagne"><noRegion><name sortKey="Tejera Vaquerizo, A" sort="Tejera Vaquerizo, A" uniqKey="Tejera Vaquerizo A" first="A" last="Tejera-Vaquerizo">A. Tejera-Vaquerizo</name>
</noRegion>
<name sortKey="Almazan, F" sort="Almazan, F" uniqKey="Almazan F" first="F" last="Almazán">F. Almazán</name>
<name sortKey="Ca Ueto, J" sort="Ca Ueto, J" uniqKey="Ca Ueto J" first="J" last="Ca Ueto">J. Ca Ueto</name>
<name sortKey="Ferrandiz Pulido, C" sort="Ferrandiz Pulido, C" uniqKey="Ferrandiz Pulido C" first="C" last="Ferrandiz-Pulido">C. Ferrandiz-Pulido</name>
<name sortKey="Fuente, M J" sort="Fuente, M J" uniqKey="Fuente M" first="M J" last="Fuente">M J Fuente</name>
<name sortKey="Jaka, A" sort="Jaka, A" uniqKey="Jaka A" first="A" last="Jaka">A. Jaka</name>
<name sortKey="Moreno Ramirez, D" sort="Moreno Ramirez, D" uniqKey="Moreno Ramirez D" first="D" last="Moreno-Ramírez">D. Moreno-Ramírez</name>
<name sortKey="Nagore, E" sort="Nagore, E" uniqKey="Nagore E" first="E" last="Nagore">E. Nagore</name>
<name sortKey="Podlipnik, S" sort="Podlipnik, S" uniqKey="Podlipnik S" first="S" last="Podlipnik">S. Podlipnik</name>
<name sortKey="Sanmartin, O" sort="Sanmartin, O" uniqKey="Sanmartin O" first="O" last="Sanmartín">O. Sanmartín</name>
<name sortKey="Santos Juanes, J" sort="Santos Juanes, J" uniqKey="Santos Juanes J" first="J" last="Santos-Juanes">J. Santos-Juanes</name>
<name sortKey="Toll, A" sort="Toll, A" uniqKey="Toll A" first="A" last="Toll">A. Toll</name>
</country>
<country name="Italie"><noRegion><name sortKey="Ribero, S" sort="Ribero, S" uniqKey="Ribero S" first="S" last="Ribero">S. Ribero</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/LockdownV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000841 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000841 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    LockdownV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32513393
   |texte=   [Estimated Effect of COVID-19 Lockdown on Skin Tumor Size and Survival: An Exponential Growth Model].
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32513393" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a LockdownV1

This area was generated with Dilib version V0.6.38.
Data generation: Sun Jan 31 08:28:27 2021. Site generation: Sun Jan 31 08:33:49 2021

	Serveur d'exploration sur le confinement (PubMed)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le confinement (PubMed)

[Estimated Effect of COVID-19 Lockdown on Skin Tumor Size and Survival: An Exponential Growth Model].

[Estimated Effect of COVID-19 Lockdown on Skin Tumor Size and Survival: An Exponential Growth Model].

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki